Literature DB >> 22706177

Postsurgical treatment of early-stage breast cancer with electronic brachytherapy: outcomes and health-related quality of life at 1 year.

Rakesh R Patel1, Peter D Beitsch, Timothy D Nichols, John D Lorenzetti, James C Wurzer, James C Tucker, George W Nunn, Susan J Laduzinsky, Morris A Kugler, Dwelvin L Simmons, Michael S Gilligan, Tapan Roy, Jonathon K Foley, John P Thropay, Mark William Odou, Bruce A Bornstein, Elizabeth P Tito, Manjeet Chadha, Susan K Boolbol, Steven C Lane, Julie G White.   

Abstract

OBJECTIVES: This multicenter registry followed up patients with early-stage breast cancer treated with breast-conserving surgery and electronic brachytherapy (EBT). This report provides 1- and 2-year updates to the initial publication.
METHODS: Patients were of age 50 years or more with invasive carcinoma or ductal carcinoma in situ, tumor size ≤3 cm, and negative surgical margins. After lumpectomy, patients received EBT in 10 fractions over 5 days (34 Gy total).
RESULTS: Of the 69 patients enrolled, 62 were evaluated at 1 year and 20 patients at 2 years after treatment. At 1 year, 28 (45.2%) patients reported adverse events that were possibly, probably, or definitely related to treatment. Most (90%) were grade 1: manageable and typical of radiation therapy. Four events were grade 2: induration/firmness (2), field contracture (1), and seroma (1). One event was grade 3: a draining fistula at the lumpectomy site due to residual effects of a breast infection at 1 month. No recurrences have been reported. Cosmetic ratings were excellent or good in 93.4% of patients at 1 year. Most patients (69%) were energetic most or all of the time. Most patients (69% to 98%) were not affected by individual symptoms of breast disease at 1 year. Generally patients who had an adverse event did not report the corresponding symptom on the quality-of-life questionnaire.
CONCLUSIONS: This registry followed up patients with early-stage breast cancer at 1 and 2 years after breast-conserving surgery and EBT. No recurrences have been reported, and adverse effects were acceptable.

Entities:  

Mesh:

Year:  2013        PMID: 22706177     DOI: 10.1097/COC.0b013e31825493bb

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  2 in total

1.  Incorporation of Electronic Brachytherapy for Skin Cancer into a Community Dermatology Practice.

Authors:  Stephen Doggett; Mark Willoughby; Cole Willoughby; Erick Mafong; Amy Han
Journal:  J Clin Aesthet Dermatol       Date:  2015-11

2.  Investigation of a source model for a new electronic brachytherapy tandem by film measurement.

Authors:  Elijah Martin; Keith Sowards; Brian Wang
Journal:  J Appl Clin Med Phys       Date:  2018-08-13       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.